Comparison of the antiplatelet effect of clopidogrel hydrogenosulfate and clopidogrel besylate in patients with stable coronary artery disease

被引:5
作者
Hamilos, Michalis [1 ]
Saloustros, Ilias [1 ]
Skalidis, Emmanuel [1 ]
Igoumenidis, Nikolaos [1 ]
Kambouris, Marios [1 ]
Chlouverakis, Grigorios [1 ]
Vougia, Despina [1 ]
Loggakis, Ioannis [1 ]
Vardas, Panos E. [1 ]
Kochiadakis, George [1 ]
机构
[1] Univ Hosp Heraklion, Dept Cardiol, Iraklion 71110, Crete, Greece
关键词
Clopidogrel; Clopidogrel salts; Platelet reactivity; Polymorphism; PLATELET REACTIVITY; ATHEROTHROMBOTIC EVENTS; CLINICAL-OUTCOMES; INCREASED RISK; ASPIRIN; POLYMORPHISMS; INTERVENTION; INHIBITION; RESISTANCE; CYP3A5;
D O I
10.1007/s11239-015-1173-y
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
It is well known that patients with poor response to antiplatelet therapy are most likely to have more thrombotic events. Clopidogrel hydrogensulfate (CHS) is a thienopyridine acting as an important antiplatelet agent alone or in combination with acetylsalicylic acid to prevent cardiovascular complications. A different clopidogrel salt, clopidogrel besylate (CB), was recently approved as a generic drug for the same purpose while data about its antiplatelet effect are very scarce. Our study compared the antiplatelet effect of CHS and CB in patients with stable coronary artery disease. Patients with stable coronary artery disease (n = 101) (coronary lesions defined angiographically 30-70 %) were randomized to either CHS (n = 50) or CB (n = 51). After randomization a 600 mg loading dose of the drug was given and monitoring of antiplatelet effect was done 12-14 h later with VerifyNow assay. Antiplatelet response was measured with P2Y12 reaction units (PRU) and % inhibition P2Y12 from baseline (% inhibition P2Y12). Moreover CYP2C19*2, CYP2C19*3 and CYP3I5 polymorphisms were studied in all patients. Clinical characteristics were similar between the two study groups. No significant difference was observed for baseline platelet reactivity between CHS and CB patients (258 +/- A 38 vs. 256 +/- A 38 respectively, p = 0.79). No difference was found for antiplatelet response between the CHS and the CB group, assessed by PRU (195 +/- A 74 vs. 204 +/- A 67 respectively, p = 0.51) and by % inhibition P2Y12 (24 +/- A 25 vs. 24 +/- A 22 % respectively, p = 0.95). Number of heterozygotes for CYP2C19*2 polymorphism was comparable and their platelet reactivity was similar between the two study groups. Our results indicate that both CB and CHS had an identical antiplatelet effect in patients with stable coronary artery disease. No difference on platelet reactivity of heterozygotes for CYP2C19*2 polymorphism was found between the two study groups.
引用
收藏
页码:288 / 293
页数:6
相关论文
共 24 条
[1]   Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population [J].
Arvanitidis, Kostas ;
Ragia, Georgia ;
Iordanidou, Maria ;
Kyriaki, Sofia ;
Xanthi, Athanasia ;
Tavridou, Anna ;
Manolopoulos, Vangelis G. .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2007, 21 (04) :419-426
[2]   What lessons can be learned from the launch of generic clopidogrel? [J].
Baumgartel, Christoph ;
Godman, Brian ;
Malmstrom, Rickard E. ;
Andersen, Morten ;
Abuelkhair, Mohammed ;
Abdu, Shajahan ;
Bennie, Marion ;
Bishop, Iain ;
Burkhardt, Thomas ;
Fahmy, Sahar ;
Furst, Jurij ;
Garuoliene, Kristina ;
Herholz, Harald ;
Kalaba, Marija ;
Koskinen, Hanna ;
Laius, Ott ;
Lonsdale, Julie ;
Malinowska, Kamila ;
Ringerud, Anne M. ;
Schwabe, Ulrich ;
Sermet, Catherine ;
Skiold, Peter ;
Teixeira, Ines ;
van Woerkom, Menno ;
Vitry, Agnes ;
Voncina, Luka ;
Zara, Corrine ;
Gustafsson, Lars L. .
GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL, 2012, 1 (02) :58-68
[3]   The effect of clopidogrel besylate and clopidogrel hydrogensulfate on platelet aggregation in patients with coronary artery disease: A retrospective study [J].
Borsiczky, Balazs ;
Sarszegi, Zsolt ;
Konyi, Attila ;
Szabados, Sandor ;
Gaszner, Balazs .
THROMBOSIS RESEARCH, 2012, 129 (06) :700-703
[4]   Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease [J].
Furman, MI ;
Benoit, SE ;
Barnard, MR ;
Valeri, CR ;
Borbone, ML ;
Becker, RC ;
Hechtman, HB ;
Michelson, AD .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 31 (02) :352-358
[5]   Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation [J].
Geisler, Tobias ;
Langer, Harald ;
Wydymus, Magdalena ;
Goehring, Katrin ;
Zuern, Christine ;
Bigalke, Boris ;
Stellos, Konstantinos ;
May, Andreas E. ;
Gawaz, Meinrad .
EUROPEAN HEART JOURNAL, 2006, 27 (20) :2420-2425
[6]   Clopidogrel resistance? [J].
Gurbel, Paul A. ;
Tantry, Udaya S. .
THROMBOSIS RESEARCH, 2007, 120 (03) :311-321
[7]  
Hjalmarson Å, 1999, LANCET, V353, P2001
[8]  
Jeong Young-Hoon, 2010, Korean Journal of Internal Medicine, V25, P154, DOI 10.3904/kjim.2010.25.2.154
[9]   Clinical Impact of Genetically Determined Platelet Reactivity [J].
Laine, Marc ;
Armero, Sebastien ;
Peyrol, Michael ;
Sbragia, Pascal ;
Thuny, Franck ;
Paganelli, Franck ;
Bonello, Laurent .
JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH, 2013, 6 (03) :398-403
[10]   Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y1® rapid analyzer:: The VERIfy Thrombosis risk ASsessment (VERITAS) study [J].
Malinin, Alex ;
Pokov, Alex ;
Spergling, Malcolm ;
Defranco, Anthony ;
Schwartz, Kenneth ;
Schwartz, Dianne ;
Mahmud, Ehtisham ;
Atar, Dan ;
Serebruany, Victor .
THROMBOSIS RESEARCH, 2007, 119 (03) :277-284